Thrombocytopenia

Platelet levels reversible in hepatitis C patients on consensus interferon

Published in Blood Weekly, December 5th, 2002

by Sonia Nichols, senior medical writer - Consensus interferon can lower platelet counts and increase serum thrombopoietin in individuals with chronic hepatitis C, but those changes are typically reversible, researchers say.

Researchers across the world are presently evaluating consensus interferon (CIFN) for use as monotherapy or in combination with ribavirin as a treatment for chronic hepatitis C. Interferon therapy is linked to the evolution of thrombocytopenia, or low platelet counts in the serum of patients infected with hepatitis C virus (HCV). Even so, medical investigators in Taiwan have announced changes in platelet counts and serum thrombopoietin levels are...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-12-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry